GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2009

Ligand Earns $1M Milestone from Schering-Plough

  • Ligand Pharmaceuticals earned a $1 million milestone payment from Schering-Plough related to the progress of Schering-Plough’s inhibitor of b-site of APP cleaving enzyme (BACE) for the treatment of Alzheimer's disease.

    The milestone payment arises from a drug discovery agreement between Schering-Plough and Pharmacopeia (acquired by Ligand), wherein Pharmacopeia contributed to Schering-Plough’s medicinal chemistry optimization programs.

    Under the terms of the collaboration agreement, Ligand is eligible to receive additional payments from Schering-Plough upon the achievement of certain development and regulatory milestones. Ligand is also eligible to receive royalties on potential sales of the drug. In addition to the BACE program, the collaboration with Schering-Plough has resulted in several Phase I and II programs in multiple therapeutic areas.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?